Published in Pharmacol Res Perspect on May 30, 2016
Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med (2014) 8.73
'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis (2012) 5.70
Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA (2011) 4.70
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation (2013) 3.53
A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol (2011) 2.51
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care (2014) 1.86
Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes (2013) 1.74
Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol (2001) 1.61
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol (2012) 1.51
Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications (2002) 1.39
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol (2013) 1.29
The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol (2007) 1.27
Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J Am Soc Nephrol (2009) 1.23
Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy? PLoS One (2013) 1.20
SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract (2014) 1.19
Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One (2014) 1.15
Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther (2013) 1.12
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol (2013) 1.10
Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. Diabetes (2011) 1.07
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf (2014) 1.06
The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism (2014) 1.04
Diabetic nephropathy and proximal tubule ROS: challenging our glomerulocentricity. Kidney Int (2007) 1.00
Renal glucose transporters: novel targets for hyperglycemia management. Nat Rev Nephrol (2010) 0.98
Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One (2014) 0.94
Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab (2014) 0.91
Tubulointerstitial disease in diabetic nephropathy. Int J Nephrol Renovasc Dis (2014) 0.82
Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab Res Rev (2013) 0.81